Age (years)b
|
43 ± 13 (24-68)
|
Gender, malec
|
31 (91%)
|
Height (cm)b
|
160 ± 7 (146-179)
|
Weight (kg)b
|
84 ± 17 (54-134)
|
BMI (kg/m2)b,d
|
32.5 ± 5.5 (21.6-47.0)
|
Normalc
|
1 (2.9%)
|
Overweightc,d
|
4 (12%)
|
Obesityc,
|
29 (85%)
|
Estimated CrCL (mL/min)b,e,
|
87 ± 31 (25-165)
|
15 ≤ Estimated CrCL < 30
|
1 (3%)
|
30 ≤ Estimated CrCL < 60
|
8 (24%)
|
Estimated CrCL ≥ 60
|
25 (74%)
|
Baseline serum urate (mg/dL)b
|
9.61 ± 1.67 (5.8-13.0)
|
Post-treatment serum urate (mg/dL)b
|
5.4 ± 1.1 (3.1 – 7)
|
Self-reported medications related to SU/gout
c,f |
|
Drugs that lower serum urate
|
10 (29%)
|
Losartan
|
1 (2.9%)
|
HMG-CoA inhibitors
|
5 (15%)
|
Calcium channel blockers
|
5 (15%)
|
Drugs that increase serum urate
|
22 (65%)
|
Angiotensin converting enzyme inhibitors
|
5 (15%)
|
Angiotensin receptor blockers (not losartan)
|
1 (2.9%)
|
Beta-blockers
|
6 (18%)
|
Diuretics
|
4 (12%)
|
Non-steroidal anti-inflammatory drugs
|
16 (47%)
|